Can bacitracin treat bacterial infections that bortezomib can't?

Bacitracin and bortezomib don't compete—bortezomib isn't an antibiotic and has zero antibacterial activity. Bacitracin treats minor bacterial skin infections. Bortezomib treats cancer. A cancer patient needing antibiotic coverage would use bacitracin (or another antibiotic), not bortezomib.

Is bacitracin safer than bortezomib?

Bacitracin is far safer for its intended use (topical application). Bortezomib carries significant side effects (neuropathy, low platelets) because it's a powerful cancer drug given systemically. Safety depends entirely on the indication. For a wound, bacitracin is appropriate; for multiple myeloma, bortezomib's benefits justify its risks.

Why isn't bortezomib approved in Europe like bacitracin?

Actually, the opposite is true: bortezomib is EMA-authorised in Europe, but bacitracin isn't. Bacitracin's absence from the EMA reflects Europe's preference for alternative topical antibiotics and stricter historical approvals. Bortezomib's EMA approval reflects its major role in oncology globally.

How many clinical trials have tested each compound?

[Bacitracin has about 40 clinical trials](https://clinicaltrials.gov/search?intr=bacitracin), mostly comparing topical formulations. [Bortezomib has over 1,000 clinical trials](https://clinicaltrials.gov/search?intr=bortezomib), reflecting decades of research across multiple cancer types and combination therapies.

Can I buy bacitracin or bortezomib over-the-counter?

Bacitracin ointment is available over-the-counter in pharmacies (US and Canada). Bortezomib is a controlled oncology drug available only by prescription and administered in hospital or infusion settings by oncologists.

Bacitracin vs Bortezomib: Key Differences & Uses

Bacitracin and bortezomib are both peptide-derived compounds approved by major regulatory bodies, but they operate in entirely different therapeutic spaces. Bacitracin is a topical antibiotic peptide used for skin infections and wound care—a workhorse of first aid and dermatology for decades. Bortezomib, by contrast, is an intravenous proteasome inhibitor used in oncology to treat blood cancers like multiple myeloma and mantle cell lymphoma. While both are peptide-based and FDA-approved, their mechanisms, delivery routes, clinical applications, and patient populations are fundamentally different. This comparison breaks down what sets them apart and which one might be relevant to your needs.

What Is Bacitracin?

Backtracin is a cyclic peptide antibiotic derived from the bacterium Bacillus subtilis. It's been in clinical use since the 1940s and is one of the most widely recognized topical antibiotics globally.

Mechanism: Bacitracin works by inhibiting bacterial cell wall synthesis, specifically by blocking the dephosphorylation of lipid carriers involved in peptidoglycan cross-linking. This makes it bactericidal—it kills bacteria rather than just slowing their growth.

Clinical use: Bacitracin is applied topically (on the skin) to prevent or treat minor bacterial infections in cuts, scrapes, and burns. It's often found in over-the-counter antibiotic ointments, sometimes combined with neomycin and polymyxin B (the "triple antibiotic" ointments you see in pharmacies).

Regulatory status: FDA-approved in the US, Health Canada approved, but not authorised by the EMA in Europe. This reflects its long safety history in North America and its niche (but established) role in infection prevention.

What Is Bortezomib?

Bortezomib is a synthetic dipeptide boronic acid compound that functions as a proteasome inhibitor. It was approved by the FDA in 2003 and represents a major breakthrough in cancer therapy.

Mechanism: Bortezomib binds reversibly to the 26S proteasome, blocking protein degradation in cancer cells. This causes accumulation of regulatory proteins, triggering apoptosis (programmed cell death) in malignant cells, particularly those dependent on rapid protein turnover.

Clinical use: Bortezomib is administered intravenously (or subcutaneously) and is used to treat:

Multiple myeloma (MM) — the most common adult blood cancer
Mantle cell lymphoma (MCL)
Light-chain amyloidosis
Waldenström macroglobulinemia

Regulatory status: FDA-approved in the US, EMA-authorised in Europe, and Health Canada approved. Its broad regulatory approval reflects extensive clinical trial data (over 1,000 clinical trials have tested bortezomib).

Head-to-Head: Key Differences

Mechanism of Action

Bacitracin is an antibiotic. It kills or inhibits bacteria by disrupting their cell walls. It's selective for bacterial cells and has virtually no activity against human cells.

Bortezomib is a cancer drug. It targets human proteasomes to kill rapidly dividing malignant cells. It's not antibacterial; it works entirely on the cancer cell's protein processing machinery.

Delivery Route

Bacitracin is topical only. You apply it directly to the skin. Systemic (internal) use of bacitracin is rare and not standard.

Bortezomib is systemic. It's injected intravenously or subcutaneously to reach cancer cells throughout the body.

Clinical Evidence Base

Both compounds have strong evidence, but in different areas:

Bacitracin: Long-standing clinical use since the 1940s provides decades of safety and efficacy data for topical infection prevention. With 40 registered clinical trials, most research focuses on optimising topical formulations and comparing it to other antibiotics.

Bortezomib: Over 1,000 clinical trials have evaluated bortezomib across multiple cancer types. Landmark trials like VISTA and APEX demonstrated superiority over standard chemotherapy in multiple myeloma, fundamentally changing cancer treatment outcomes.

Scope of Approved Uses

Bacitracin has a narrow, well-defined scope: minor skin infections and wound care. It's not indicated for systemic infections or internal use.

Bortezomib has a broader oncology footprint: multiple myeloma (primary indication), mantle cell lymphoma, light-chain amyloidosis, and investigational use in other blood cancers and solid tumours.

Side Effect Profiles

Bacitracin is extremely well-tolerated. Topical use rarely causes systemic toxicity. Occasional allergic contact dermatitis is the main concern.

Bortezomib carries significant toxicity risks, including:

Peripheral neuropathy (nerve damage in extremities)
Thrombocytopenia (low platelet count)
Gastrointestinal effects
Fatigue

These are managed through careful dosing and monitoring, and the benefits in cancer treatment typically outweigh risks.

Cost and Accessibility

Bacitracin is inexpensive and widely available over-the-counter in North America.

Bortezomib is a high-cost specialty oncology drug, typically given in hospital or infusion clinic settings, and requires oncologist oversight.

Patient Populations: Who Uses Each?

Bacitracin Users

Anyone with minor cuts, scrapes, or wounds wanting to prevent infection
Patients with surgical wounds requiring topical antibiotic coverage
People with superficial skin infections (impetigo, folliculitis)
Athletes, outdoor enthusiasts, and anyone prone to minor injuries

Backtracin is a preventive and minor infection tool, not a systemic solution.

Bortezomib Users

Patients newly diagnosed with multiple myeloma (often frontline therapy)
Relapsed or refractory myeloma patients (when first-line therapy fails)
Mantle cell lymphoma patients (especially relapsed/refractory)
People with rare blood cancers like light-chain amyloidosis

Bortezomib is strictly an oncology drug used under specialist care with careful monitoring.

Regulatory Comparison

| Aspect | Bacitracin | Bortezomib | |--------|-----------|----------| | FDA (US) | Approved | Approved | | EMA (EU) | Not authorised | Authorised | | Health Canada | Approved | Approved | | Clinical Trials | 40 | 1,000+ | | Evidence Grade | A | A | | Year Approved (FDA) | 1948 | 2003 |

Backtracin's absence from the EMA likely reflects its niche use case and the availability of alternative topical antibiotics in Europe. Bortezomib's broader authorisation underscores its significance in oncology globally.

Can You Use Them Together?

No clinical scenario combines bacitracin and bortezomib therapeutically. They operate in completely separate medical domains. However, a cancer patient on bortezomib could use bacitracin ointment for a minor skin wound—there would be no drug interaction, but bortezomib suppresses immune function, so even minor wounds warrant closer monitoring.

Related Peptide Compounds

If you're exploring peptide-based therapies:

Vancomycin — another cyclic peptide antibiotic, used systemically for serious bacterial infections where bacitracin won't work
Daptomycin — a lipopeptide antibiotic for bloodstream and skin infections
Carfilzomib — another proteasome inhibitor in the same drug class as bortezomib, used in multiple myeloma

For more context on how peptides work in medicine, see our guides on peptide antibiotics and proteasome inhibitors.

Bottom Line

Backtracin and bortezomib share only their peptide origin—they're tools for completely different problems. Bacitracin is a decades-old topical antibiotic for minor wounds. Bortezomib is a modern, high-impact cancer drug for blood malignancies. Neither is a substitute for the other, and they serve entirely different patient populations. If you're deciding between them, the context of your situation (minor infection vs. cancer diagnosis) makes the choice obvious.

Bacitracin vs Bortezomib: Understanding Two Distinct Peptide-Based Compounds